LYTIR

Company · LYEL

Lyell Immunopharma, Inc.

Nasdaq's symbol directory lists LYEL on Nasdaq as “Lyell Immunopharma, Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 1 occasion ($25.0M); insiders sold on 15 occasions ($231K); 1 filing by holders of 5% or more; 3 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $25.0M in total; Insider sales: $231K in total.May: Insider sales $16KJul: Insider sales $274Aug: Insider sales $205KSep: Insider sales $6KOct: Insider sales $4KNov: Insider purchases $25.0MDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $25.0MInsider sales below: $231K
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. ARCH Venture Partners IX, LLC bought on 1 day latest Nov 4, 2026 bought $25.0M
  2. Seely Lynn, President and CEO sold on 3 days latest Aug 21, 2026 sold $162K
  3. Lee Gary K., Chief Scientific Officer sold on 3 days latest Aug 21, 2026 sold $27K
  4. Hill Stephen J., Chief Operating Officer sold on 3 days latest Aug 21, 2026 sold $18K
  5. Bulis Veronica Sanchez, VP, Corporate Controller sold on 2 days latest Aug 10, 2026 sold $13K
  6. Shook David, Chief Medical Officer sold on 1 day latest Sep 10, 2026 sold $6K
  7. Aguirre Jarrad Mattieu, Chief Medical Officer sold on 1 day latest Oct 12, 2026 sold $4K
  8. Innovative Cellular Therapeutics Holdings Ltd sold on 2 days all under a 10b5-1 plan latest Jul 17, 2026 sold $274
Every trade (16)
  1. BUYARCH Venture Partners IX, LLC bought Nov 4, 2026 2,321,262 shares filing $25.0M
  2. SELLAguirre Jarrad Mattieu, Chief Medical Officer sold Oct 12, 2026 422 shares filing $4K
  3. SELLShook David, Chief Medical Officer sold Sep 10, 2026 500 shares filing $6K
  4. SELLSeely Lynn, President and CEO sold Aug 21, 2026 9,589 shares filing $149K
  5. SELLLee Gary K., Chief Scientific Officer sold Aug 21, 2026 1,457 shares filing $23K
  6. SELLHill Stephen J., Chief Operating Officer sold Aug 21, 2026 989 shares filing $15K
  7. SELLBulis Veronica Sanchez, VP, Corporate Controller sold Aug 10, 2026 621 shares filing $9K
  8. SELLSeely Lynn, President and CEO sold Aug 10, 2026 390 shares filing $6K
  9. SELLLee Gary K., Chief Scientific Officer sold Aug 10, 2026 131 shares filing $2K
  10. SELLHill Stephen J., Chief Operating Officer sold Aug 10, 2026 89 shares filing $1K
  11. SELLInnovative Cellular Therapeutics Holdings Ltd sold Jul 17, 2026 10 shares 10b5-1 plan (scheduled) filing $137
  12. SELLInnovative Cellular Therapeutics Holdings Ltd sold Jul 16, 2026 10 shares 10b5-1 plan (scheduled) filing $137
  13. SELLSeely Lynn, President and CEO sold May 11, 2026 388 shares filing $7K
  14. SELLBulis Veronica Sanchez, VP, Corporate Controller sold May 11, 2026 217 shares filing $4K
  15. SELLLee Gary K., Chief Scientific Officer sold May 11, 2026 130 shares filing $2K
  16. SELLHill Stephen J., Chief Operating Officer sold May 11, 2026 89 shares filing $2K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Foresite Capital Fund IV, L.P. filed Aug 14, 2026 Schedule 13G/A passive filing 2.7%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Nov 4, 2026
  2. Unregistered sales of equity securities filing Nov 4, 2026
  3. Other events filing Sep 10, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.